Marco Filippini To Head Mundipharma France

Jan. 21, 2014 - PRLog -- Marco Filippini, General Manager of Mundipharma Italy, took over responsibility for the French associate of Mundipharma International, a world leader in the development and commercialisation of opioid analgesics for treating pain.

With this appointment, Mundipharma France joins the group of southern European countries whichMarco Filippini has headed since 2008 as Regional Director Southern Europe, covering Italy, Spain, Portugal, Greece and Turkey.

Originally from Bollate (Milan) where he was born in 1962, now married and father of two children,Marco Filippini graduated in pharmaceutics from the University of Milan in 1987.

With more than 25 years experience in the pharmaceutical field, he has held positions of increasing responsibility in Italy and abroad working not only in sales but also in marketing for important multinational companies such as Schering Plough, Roussel Pharma, Glaxo.

In 2004, he was appointed General Manager of the Italian branch of Mundipharma, the most recent associate which has grown rapidly and is now ranked fourth in the Group for annual turnover.

Filippini’s managerial skills and his appointment as head of the French associate will enable Mundipharma International to further increase its market share in all the countries of southern Europe and the eastern Mediterranean, at the same time seeking new opportunities for growth and development.

The newly appointed General Manager of Mundipharma France, Stefaan Schatteman, will report directly to Marco Filippini.

Mundipharma
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and rheumatoid arthritis. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting-edge treatments to meet the most pressing needs of healthcare professionals and patients.

Source: Mundipharma.it